Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
Open Access
- 16 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (6), 796-806
- https://doi.org/10.1038/bjc.2011.321
Abstract
We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both trastuzumab-sensitive and trastuzumab-resistant, ErbB-2-positive, BT474 breast tumours in vivo. We also studied if the combination therapy of lapatinib plus GSI can induce tumour regression of ErbB-2-positive breast cancer. We generated orthotopic breast tumour xenografts from trastuzumab- or lapatinib-sensitive and trastuzumab-resistant BT474 cells. We investigated the antitumour activities of two distinct GSIs, LY 411 575 and MRK-003, in vivo. Our findings showed that combining trastuzumab plus a GSI completely prevented (MRK-003 GSI) or significantly reduced (LY 411 575 GSI) breast tumour recurrence post-trastuzumab treatment in sensitive tumours. Moreover, combining lapatinib plus MRK-003 GSI showed significant reduction of tumour growth. Furthermore, a GSI partially reversed trastuzumab resistance in resistant tumours. Our data suggest that a combined inhibition of Notch and ErbB-2 signalling pathways could decrease recurrence rates for ErbB-2-positive breast tumours and may be beneficial in the treatment of recurrent trastuzumab-resistant disease.Keywords
This publication has 59 references indexed in Scilit:
- Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor XenograftsClinical Cancer Research, 2011
- Targeting Notch to Target Cancer Stem CellsClinical Cancer Research, 2010
- Notch-1 and Notch-4 Receptors as Prognostic Markers in Breast CancerInternational Journal of Surgical Pathology, 2010
- Aromatase resistance mechanisms in model systems in vivoThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 ReceptorCancer Research, 2010
- The Canonical Notch Signaling Pathway: Unfolding the Activation MechanismCell, 2009
- Breast cancer cells expressing stem cell markers CD44+ CD24lo are eliminated by Numb-1 peptide-activated T cellsCancer Immunology, Immunotherapy, 2008
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- Reversal of tamoxifen resistant breast cancer by low dose estrogen therapyThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004